Kendall Capital Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.28M | Buy |
45,452
+4,007
| +10% | +$107K | 0.26% | 97 |
|
|
2025
Q4 | $1.03M | Buy |
41,445
+14,930
| +56% | +$376K | 0.22% | 115 |
|
|
2025
Q3 | $676K | Buy |
26,515
+9,115
| +52% | +$225K | 0.15% | 133 |
|
|
2025
Q2 | $422K | Buy |
+17,400
| New | +$406K | 0.11% | 156 |
|
|
2024
Q4 | – | Sell |
-10,800
| Closed | -$313K | – | 227 |
|
|
2024
Q3 | $313K | Sell |
10,800
-2,300
| -18% | -$67.1K | 0.1% | 181 |
|
|
2024
Q2 | $367K | Sell |
13,100
-20,076
| -61% | -$553K | 0.12% | 161 |
|
|
2024
Q1 | $921K | Sell |
33,176
-14,985
| -31% | -$416K | 0.32% | 96 |
|
|
2023
Q4 | $1.39M | Sell |
48,161
-5,860
| -11% | -$177K | 0.54% | 59 |
|
|
2023
Q3 | $1.79M | Buy |
54,021
+4,690
| +10% | +$166K | 0.79% | 40 |
|
|
2023
Q2 | $1.81M | Sell |
49,331
-1,510
| -3% | -$58.8K | 0.79% | 35 |
|
|
2023
Q1 | $2.07M | Buy |
50,841
+2,717
| +6% | +$117K | 1% | 22 |
|
|
2022
Q4 | $2.47M | Buy |
48,124
+5,156
| +12% | +$247K | 1.25% | 19 |
|
|
2022
Q3 | $1.88M | Buy |
42,968
+4,411
| +11% | +$214K | 1.09% | 22 |
|
|
2022
Q2 | $2.02M | Buy |
38,557
+5,134
| +15% | +$262K | 1.11% | 23 |
|
|
2022
Q1 | $1.73M | Buy |
33,423
+1,040
| +3% | +$54K | 0.84% | 32 |
|
|
2021
Q4 | $1.91M | Sell |
32,383
-50
| -0.2% | -$2.48K | 0.91% | 29 |
|
|
2021
Q3 | $1.4M | Sell |
32,433
-31
| -0.1% | -$1.37K | 0.75% | 42 |
|
|
2021
Q2 | $1.27M | Sell |
32,464
-920
| -3% | -$35.8K | 0.71% | 46 |
|
|
2021
Q1 | $1.21M | Sell |
33,384
-200
| -0.6% | -$7.1K | 0.75% | 43 |
|
|
2020
Q4 | $1.24M | Sell |
33,584
-1,972
| -6% | -$72.3K | 0.9% | 38 |
|
|
2020
Q3 | $1.24M | Sell |
35,556
-357
| -1% | -$12.5K | 1.08% | 32 |
|
|
2020
Q2 | $1.11M | Sell |
35,913
-1,454
| -4% | -$49.4K | 1.07% | 36 |
|
|
2020
Q1 | $1.16M | Sell |
37,367
-3,322
| -8% | -$113K | 1.31% | 24 |
|
|
2019
Q4 | $1.51M | Buy |
40,689
+2,061
| +5% | +$73.4K | 1.19% | 24 |
|
|
2019
Q3 | $1.32M | Buy |
38,628
+1,028
| +3% | +$37.4K | 1.16% | 27 |
|
|
2019
Q2 | $1.54M | Sell |
37,600
-1,560
| -4% | -$61.9K | 1.4% | 18 |
|
|
2019
Q1 | $1.58M | Buy |
39,160
+58
| +0.1% | +$2.32K | 1.5% | 16 |
|
|
2018
Q4 | $1.62M | Buy |
39,102
+678
| +2% | +$28.1K | 1.68% | 14 |
|
|
2018
Q3 | $1.61M | Sell |
38,424
-2,027
| -5% | -$78K | 1.37% | 20 |
|
|
2018
Q2 | $1.39M | Buy |
40,451
+7,030
| +21% | +$240K | 1.23% | 24 |
|
|
2018
Q1 | $1.13M | Buy |
33,421
+3,257
| +11% | +$112K | 0.98% | 30 |
|
|
2017
Q4 | $1.04M | Buy |
+30,164
| New | +$1.03M | 0.92% | 34 |
|
Other funds holding PFE
VCM
VPM
Kendall Capital Management's PFE Position: Q1 2026 in Review
Kendall Capital Management increased its Pfizer (PFE) stake by 9.7% in Q1 2026, buying an estimated $107K and bringing the position to 45,452 shares worth $1.28M. The position accounts for 0.26% of the portfolio, ranked #97.
Kendall Capital Management first reported a position in PFE in Q4 2017 and has held it in 32 quarters since. The position peaked at $2.47M in Q4 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Kendall Capital Management held 45,452 shares of Pfizer worth $1.28M as of Q1 2026.
- Kendall Capital Management bought 4,007 Pfizer shares in Q1 2026, an estimated $107K.
- Pfizer made up 0.26% of Kendall Capital Management's portfolio in Q1 2026, its #97 holding.
- Kendall Capital Management first reported a position in Pfizer in Q4 2017 and has held it in 32 quarters since.
- Kendall Capital Management's Pfizer position peaked at $2.47M in Q4 2022.
- 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Kendall Capital Management's 13F filing for Q1 2026, filed 24 Apr 2026.